Pharmafile Logo
Pharmafocus logo
Advanced Search

Lynparza granted approval to treat prostate cancer in Japan

August 25, 2023
Research and Development Merck, Oncology, astra zeneca, prostate cancer

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …

News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

August 24, 2023
Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …

News
hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023
Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …

News

GSK confirms positive results from shingles trial in China

August 23, 2023
Research and Development GSK, Infections and infestations, clinical trials, shingles

GSK has announced positive results today from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China. These …

News
lungs

Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC

August 23, 2023
Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan

Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …

News

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …

News
money-pills-pharma-file

LEO Pharma to acquire Timber Pharmaceuticals for up to $36m

August 22, 2023
Business Services Dermatology, LEO Pharma, Timber Pharmaceuticals, acquisition

Timber Pharmaceuticals has announced that it has entered a definitive agreement to be acquired by LEO Pharma, with a total …

News

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023
Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …

News

FDA approves Pfizer’s vaccine for the prevention of RSV in children

August 22, 2023
Research and Development FDA, Paediatrics, Pfizer, RSV

On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory …

News

Recce Pharmaceuticals shares data from phase 1/2 trial for burn wound infection

August 21, 2023
Research and Development Recce Pharmaceuticals, Wound Healing, burn wounds, clinical trial, infection

Recce Pharmaceuticals has announced that it has completed its data analysis for its phase 1/2 clinical trial of Recce 327 …

News
blood-1813410_960_720

Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023
Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …

News

FDA approves first ever treatment for rare CHAPLE disease

August 21, 2023
Research and Development CHAPLE disease, FDA, Rare Diseases, rare disease

The US Food and Drug Administration (FDA) has approved Regeneron’s Veopoz (pozelimab), a new treatment for CHAPLE disease for both …

News

Destiny Pharma appoints new CEO Chris Tovey

August 21, 2023
Business Services CEO, Chris Tovey, Destiny Pharma, Infections and infestations

Destiny Pharma has announced the appointment of Chris Tovey, who will be replacing Dr Debra Barker as chief executive officer; …

Appointment

FDA approves IMIDEX’s AI-powered device VisiRad XR

August 18, 2023
Research and Development FDA, Radiology, pharma, radiology

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug Administration (FDA) for its artificial …

News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …

News

Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA

August 18, 2023
Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …

News

Dr Michael Lutz appointed as new chief executive officer of iotaSciences

August 18, 2023
Business Services Dr Michael Lutz, Haematology, chief executive officer, iotasciences

The pharmaceutical discovery company iotaSciences has announced that it has appointed Dr Michael Lutz as its new chief executive officer. …

Appointment

Foghorn Therapeutics appoints Alfonso Quintás-Cardama as new chief medical officer

August 18, 2023
Business Services Alfonso Quintas-Cardama, Foghorn Therapeutics, Haematology, chief medical officer

The biotechnology company Foghorn Therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be …

Appointment

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

News

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

August 17, 2023
Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …

News
The Gateway to Local Adoption Series

Latest content

PSI announces new Osaka office as part of Japanese expansion

January 12, 2026

Teva’s Ajovy significantly reduces migraine in children and adolescents

January 12, 2026

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026